30 years of historical data (1996–2025) · Healthcare · Drug Manufacturers - General
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Pfizer Inc. trades at 20.3x earnings, 27% below its 5-year average of 27.9x, sitting at the 53rd percentile of its historical range. Compared to the Healthcare sector median P/E of 23.7x, the stock trades at a discount of 14%.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $157.2B | $141.6B | $151.2B | $164.4B | $293.8B | $337.1B | $207.3B | $210.8B | $247.3B | $208.0B | $189.6B |
| Enterprise Value | $157.2B | $141.6B | $217.2B | $232.4B | $328.2B | $372.1B | $243.8B | $260.5B | $287.9B | $249.2B | $228.1B |
| P/E Ratio → | 20.33 | 18.31 | 18.82 | 77.56 | 9.37 | 15.22 | 22.64 | 12.95 | 22.18 | 9.76 | 26.32 |
| P/S Ratio | 2.51 | 2.26 | 2.38 | 2.76 | 2.93 | 4.15 | 4.98 | 5.12 | 4.61 | 3.96 | 3.59 |
| P/B Ratio | 1.69 | 1.52 | 1.71 | 1.84 | 3.06 | 4.35 | 3.27 | 3.32 | 3.88 | 2.90 | 3.17 |
| P/FCF | — | — | 15.38 | 34.29 | 11.28 | 11.28 | 17.85 | 21.09 | 18.14 | 14.59 | 13.64 |
| P/OCF | — | — | 11.87 | 18.89 | 10.04 | 10.35 | 14.39 | 16.74 | 15.63 | 12.63 | 11.93 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
Pfizer Inc.'s enterprise value stands at 7.7x EBITDA, 34% below its 5-year average of 11.7x. The Healthcare sector median is 13.8x, placing the stock at a 44% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.26 | 3.41 | 3.90 | 3.27 | 4.58 | 5.85 | 6.33 | 5.37 | 4.74 | 4.32 |
| EV / EBITDA | 7.73 | 6.96 | 9.24 | 20.06 | 7.70 | 14.32 | 17.71 | 19.58 | 13.29 | 12.06 | 11.39 |
| EV / EBIT | 10.18 | 13.89 | 19.54 | 71.12 | 9.13 | 14.53 | 28.73 | 19.95 | 21.81 | 18.36 | 23.92 |
| EV / FCF | — | — | 22.08 | 48.48 | 12.61 | 12.46 | 21.00 | 26.06 | 21.12 | 17.49 | 16.41 |
Margins and return-on-capital ratios measuring operating efficiency
Pfizer Inc. earns an operating margin of 24.7%. Operating margins have expanded from 8.9% to 24.7% over the past 3 years, signaling improving operational efficiency. ROE of 8.6% is modest. ROIC of 9.4% represents adequate returns on invested capital.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 70.3% | 70.3% | 65.8% | 50.9% | 61.9% | 57.7% | 71.7% | 69.3% | 70.2% | 70.0% | 69.8% |
| Operating Margin | 24.7% | 24.7% | 25.9% | 8.9% | 37.4% | 25.6% | 21.8% | 18.2% | 28.5% | 27.4% | 27.0% |
| Net Profit Margin | 12.4% | 12.4% | 12.6% | 3.6% | 31.3% | 27.2% | 22.0% | 39.5% | 20.8% | 40.5% | 13.7% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 8.6% | 8.6% | 9.0% | 2.3% | 36.2% | 31.4% | 14.4% | 25.6% | 16.5% | 32.4% | 11.6% |
| ROA | — | — | 3.6% | 1.0% | 16.6% | 13.2% | 5.7% | 10.0% | 6.7% | 12.4% | 4.3% |
| ROIC | 9.4% | 9.4% | 7.9% | 2.8% | 23.2% | 14.7% | 6.4% | 5.2% | 10.6% | 10.2% | 10.8% |
| ROCE | — | — | 9.4% | 3.2% | 25.6% | 15.6% | 7.0% | 5.8% | 11.4% | 10.2% | 10.2% |
Solvency and debt-coverage ratios — lower is generally safer
Interest coverage of 5.8x is adequate, though a cyclical earnings downturn could tighten the margin of safety.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.76 | 0.79 | 0.36 | 0.48 | 0.60 | 0.80 | 0.65 | 0.59 | 0.69 |
| Debt / EBITDA | — | — | 2.85 | 6.12 | 0.82 | 1.42 | 2.78 | 3.82 | 1.93 | 2.06 | 2.05 |
| Net Debt / Equity | — | 0.00 | 0.75 | 0.76 | 0.36 | 0.45 | 0.57 | 0.78 | 0.64 | 0.58 | 0.64 |
| Net Debt / EBITDA | — | 0.00 | 2.81 | 5.87 | 0.81 | 1.35 | 2.65 | 3.74 | 1.87 | 2.00 | 1.92 |
| Debt / FCF | — | — | 6.71 | 14.19 | 1.32 | 1.17 | 3.14 | 4.97 | 2.98 | 2.90 | 2.77 |
| Interest Coverage | 5.78 | 5.78 | 5.33 | 2.40 | 30.33 | 16.11 | 6.27 | 4.77 | 11.62 | 11.33 | 12.04 |
Short-term solvency ratios and asset-utilisation metrics
The current ratio has improved from 0.91x to 1.17x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | — | — | 1.17 | 0.91 | 1.22 | 1.40 | 1.35 | 0.88 | 1.57 | 1.35 | 1.25 |
| Quick Ratio | — | — | 0.92 | 0.69 | 1.00 | 1.19 | 1.04 | 0.69 | 1.33 | 1.10 | 1.03 |
| Cash Ratio | 0.48 | — | 0.48 | 0.27 | 0.54 | 0.73 | 0.47 | 0.26 | 0.59 | 0.66 | 0.57 |
| Asset Turnover | — | — | 0.30 | 0.26 | 0.51 | 0.45 | 0.27 | 0.25 | 0.34 | 0.31 | 0.31 |
| Inventory Turnover | 2.01 | — | 2.01 | 2.87 | 4.26 | 3.80 | 1.46 | 1.79 | 2.13 | 2.08 | 2.35 |
| Days Sales Outstanding | — | — | 84.77 | 95.27 | 52.86 | 70.70 | 97.95 | 84.29 | 77.56 | 78.29 | 77.85 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Pfizer Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 4.9% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | 6.3% | 5.6% | 3.1% | 2.6% | 4.1% | 3.8% | 3.2% | 3.7% | 3.9% |
| Payout Ratio | — | — | 118.6% | 433.5% | 28.6% | 39.4% | 92.1% | 49.4% | 71.5% | 35.9% | 101.4% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 4.9% | 5.5% | 5.3% | 1.3% | 10.7% | 6.6% | 4.4% | 7.7% | 4.5% | 10.2% | 3.8% |
| FCF Yield | — | — | 6.5% | 2.9% | 8.9% | 8.9% | 5.6% | 4.7% | 5.5% | 6.9% | 7.3% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.7% | 0.0% | 0.0% | 4.2% | 4.9% | 2.4% | 2.6% |
| Total Shareholder Yield | 0.0% | 0.0% | 6.3% | 5.6% | 3.7% | 2.6% | 4.1% | 8.0% | 8.2% | 6.1% | 6.5% |
| Shares Outstanding | — | $5.7B | $5.7B | $5.7B | $5.7B | $5.7B | $5.6B | $5.7B | $6.0B | $6.1B | $6.2B |
Compare PFE with 4 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| PFEYou | $157B | 20.3 | 7.7 | — | 70.3% | 24.7% | 8.6% | 9.4% | — |
| MRK | $307B | 17.0 | 9.9 | — | 81.5% | 41.2% | 37.1% | 32.6% | — |
| GSK | $119B | 16.2 | 9.6 | 15.1 | 72.5% | 21.9% | 38.5% | 18.6% | 1.7 |
| SNY | $118B | 20.3 | 11.9 | 11.2 | 72.3% | 13.6% | 10.4% | 5.5% | 2.3 |
| GRFS | $2B | 33.5 | 6.8 | 3.8 | 38.7% | 16.5% | 1.9% | 5.0% | 6.2 |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 30 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how PFE stacks up against sector leader Merck & Co., Inc..
Start ComparisonPfizer Inc.'s current P/E ratio is 20.3x. The historical average is 26.5x. This places it at the 53th percentile of its historical range.
Pfizer Inc.'s current EV/EBITDA is 7.7x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 14.5x.
Pfizer Inc.'s return on equity (ROE) is 8.6%. The historical average is 20.2%.
Based on historical data, Pfizer Inc. is trading at a P/E of 20.3x. This is at the 53th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Pfizer Inc. has 70.3% gross margin and 24.7% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.